Trillium Therapeutics

Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted proteins, and peptides. It involves in therapeutic areas, including autoimmune disease, cancer, necrotizing enterocolitis, and transplantation. Trillium Therapeutics Inc. was formerly known as Transplantation Technologies Inc. and changed its name in May 2003. The company was founded in 1996 and is based in Toronto, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MicroSectors U.S. Big Banks Index -3X Inverse Leveraged ETN

Celsius Holdings

Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 2X Shares

Enphase Energy

Direxion Daily Financial Bear 3X Shares

Intel

Direxion Daily S&P Biotech Bear 3X Shares

Microsoft

NVIDIA

Riot Blockchain

Direxion Daily Small Cap Bear 3x Shares

ProShares Ultra VIX Short-Term Futures ETF

Two new Breakout Stocks for Week 12 with better than 10% short-term upside with ETFs and a Dow 30 Pick. Average cumulative returns for 2023 are +37.3% YTD. The Momentum Gauges® continue negative in bear funds from Mar 7th led by BNKD +65.7%. EGO peaked at +8.3% gains for members.

MDA Breakout Stocks/ETFs Week 12 - March 2023: High-Frequency Gainers To Give You An Edge

American Express

Cisco Systems

Direxion Daily Energy Bear 2X Shares

Genco Shipping & Trading

Goldman Sachs

Home Depot

Intrepid Potash

Coca-Cola

MGP Ingredients

Brigham Minerals

NIKE

Direxion Daily Semiconductor Bear 3x Shares

Tidewater

Visa

Two new Breakout Stocks for Week 27 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +85.6% YTD.

Week 27 MDA Breakout Stocks - July 2022: Short-Term Picks To Give You An Edge

Amgen

Caterpillar

Chevron

Loop Industries

Merck

Ouster, Inc

Procter & Gamble

Travelers

Walmart

Two sample Breakout Stocks for Week 13 with better than 10% short-term upside potential and a Dow stock pick.

Week 13 MDA Breakout Stocks - April 2022: Short-Term Picks To Give You An Edge

Centennial Resource Development

Civitas Resources

Dow Inc

Honeywell

ProPetro Hld

Verizon

Two sample Breakout Stocks for Week 3 with better than 10% short-term upside potential and a Dow stock pick. This past week was a negative momentum signal and no picks beat 10% peak gains with the picks down -0.08% in total led by TDW +4% and HXL +2.1%.

Week 3 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge

Winnebago

Two sample Breakout Stocks for Week 2 with better than 10% short-term upside potential and a Dow stock pick. This past week, 3 stocks beat 10% peak gains with RES +29.2%, UGRO +11.0%, and DYAI +10.2% with Momentum Gauge® values still high negative.

Week 2 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge

Dyadic International Inc., DE

Urban-gro

Two sample Breakout Stocks for Week 1 with better than 10% short-term upside potential and a Dow stock pick. This past week 1 stock beat 10% peak gains with AEHR +27.2% and METC +8.6% with Momentum Gauge® values still negative.

Week 1 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge

Apple

Aehr Test Systems

Codexis

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Two sample Breakout Stocks for Week 52 with better than 10% short-term upside potential and a Dow stock pick. This past week, two stocks beat 10% peak gains in FLGT +19.1% and DYAI +13.8% with Momentum Gauge® values improving through the week.

Week 52 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

Johnson & Johnson

Quanex Building Products

Two sample Breakout Stocks for Week 51 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. This past week, 1 stock beat 10% peak gains in BYFC +28.2% despite high negative Momentum Gauge® values from November continuing through the week.

Week 51 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

McDonald's

Two sample Breakout Stocks for Week 50 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. This past week 1 stock beat 10% peak gains in HIMX +13.2% despite high negative Momentum Gauge® values from November continuing through the week.

Week 50 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

Himax Tech

Two sample Breakout Stocks for Week 49 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. This past week 2 stocks beat 10% peak gains with VIR +39.9% and GRTS +26.5% despite very high negative Momentum Gauge® signals and large market declines.

Week 49 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

Citigroup

Gritstone Oncology Inc

GlaxoSmithKline

Pfizer

Vir Biotechnology

Two sample Breakout Stocks for Week 48 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 26 weeks out 47 weeks this year in negative conditions above the 40 MG level.

Week 48 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the “Arrangement”) with PF Argentum ULC (“PF Argentum”), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”).

Trillium Therapeutics Receives Final Court Order Approving Arrangement

CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (“PF Argentum”) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”) at the special meeting of Trillium securityholders today. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates.

Trillium Securityholders Approve Acquisition by Pfizer

NEW YORK, Sept. 11, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Trillium Therapeutics, Inc. ("TRIL" or the "Company") (TRIL) relating to its proposed acquisition by Landmark Dividend LLC.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Trillium Therapeutics, Inc. - TRIL

This deal checks off several boxes for Pfizer.

Why Investors Should Love Pfizer's Acquisition of Trillium

Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.

Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Trillium Therapeutics Inc. (NASDAQ: TRIL) to Pfizer Inc. for $18.50 per share in cash is fair to Trillium shareholders. Halper Sadeh encourages Trillium shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Tri

Trillium Therapeutics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Trillium Therapeutics Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – TRIL

Virtus LifeSci Biotech Clinical Trials ETF

Loncar Cancer Immunotherapy ETF

Defiance Nasdaq Junior Biotechnology ETF

ALPS Medical Breakthroughs ETF

SPDR S&P Biotech ETF

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

What do you do when you're brimming with billions of dollars in new vaccine revenue? You splurge, of course!

Pfizer To Buy Cancer Biotech Company Trillium For $2.3 Million

AMC Entertainment

BioNTech SE

Coinbase

FuelCell Energy

Canoo

Moderna

Plug Power

Romeo Power

Starbucks

Tesla

So what did the stock market do today? Investors cheered on Pfizer stock and rallied behind infrastructure plays.

What Did the Stock Market Do Today, Aug. 23? 3 Big Stories to Catch Up On.

The drugmaker's own stock is up 3% Monday morning, but that's nothing compared to the impact it's having on a couple of other healthcare companies.

Dual Wins for Pfizer Mean Big Jumps for These 2 Stocks

TRIL stock is soaring to nearly triple its Friday prices. Pfizer is acquiring the oncology company in a multi-billion dollar deal.

TRIL Stock: The Huge $2.3B Deal Sending Trillium Therapeutics Up 200%

Pfizer said it will pay $18.50 a share for the Cambridge, Massachusetts-based drug maker Trillium.

Pfizer to buy cancer drug maker Trillium for $2.3B

Pfizer may have gotten a fantastic deal on this clinical-stage oncology company.

Why Trillium Therapeutics Stock Is Skyrocketing Today

Pfizer had originally invested $25 million in Trillium in September of last year, as part of its breakthrough growth initiative.

Trillium Therapeutics soars 200% after Pfizer inks deal to buy cancer-drug company for $2.3 billion

News for Trillium Therapeutics Stock (TRIL)